Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR8YD6)

• Drug Name: B-Lactams Drug Info
• Synonyms: Luteolin; luteolin; 491-70-3; Luteolol; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one; Luteoline; Digitoflavone; Flacitran; Weld Lake; Cyanidenon 1470; Salifazide; Yama kariyasu; 5,7,3',4'-Tetrahydroxyflavone; UNII-KUX1ZNC9J2; CI Natural Yellow 2; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; 7-Tetrahydroxyflavone; CCRIS 3790; EINECS 207-741-0; KUX1ZNC9J2; CHEMBL151; BRN 0292084; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1]

• Cross-matching ID:
  PubChem CID: 5280445
  ChEBI ID: CHEBI:15864
  CAS Number: CAS 491-70-3
  TTD Drug ID: DMR8YD6

Molecule-Related Drug Atlas

Drug(s) Targeting DNA topoisomerase I (TOP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[4]
Topotecan	DMP6G8T	Central nervous system neoplasm		Approved	[4]
Belotecan hydrocholoride	DM3SRJZ	Small-cell lung cancer	2C25.Y	Approved	[5]
Topetecan	DMAE6LK	Small-cell lung cancer	2C25.Y	Approved	[6]
Karenitecin	DMCRGY4	Lung cancer	2C25.0	Phase 3	[7]
Camptothecin	DM6CHNJ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
Exatecan	DMCA7FN	Solid tumour/cancer	2A00-2F9Z	Phase 3	[9]
Edotecarin	DM3ZL7D	Gastric adenocarcinoma	2B72	Phase 3	[10]
Rubitecan	DMDWU1S	Human immunodeficiency virus infection	1C62	Phase 3	[11]
Etirinotecan pegol	DMQHX1Y	Breast cancer	2C60-2C65	Phase 3	[12]

Drug(s) Targeting Acetyl-CoA:lyso-PAF acetyltransferase (PCAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]

Drug(s) Targeting Bacterial DD-carboxypeptidase (Bact vanYB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cefalotin	DMVYSLE	Bacteremia	1A73	Approved	[14]
Cephalosporin	DM79XDW	Bacterial infection	1A00-1C4Z	Approved	[15]
Cefotaxime	DMEB837	Bacteremia	1A73	Approved	[16]
TD-1792	DMGKBZH	Skin infection	1F28-1G0Z	Phase 3	[17]
Phenyl Boronic acid	DMFZH49	Discovery agent	N.A.	Investigative	[18]
Cephalosporin C	DMYW3ZG	Discovery agent	N.A.	Investigative	[19]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[20]
D-Alanine	DMVIDQL	Discovery agent	N.A.	Investigative	[20]
3-boronobenzoic acid	DMRCJW0	Discovery agent	N.A.	Investigative	[18]
NITROCEFIN	DM7M5VY	Discovery agent	N.A.	Investigative	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Acetyl-CoA:lyso-PAF acetyltransferase (PCAT)	TTPOI4B	PCAT1_HUMAN; PCAT2_HUMAN	Inhibitor	[2]
Bacterial DD-carboxypeptidase (Bact vanYB)	TTLP6GN	VANY_ENTFA	Inhibitor	[1]
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Inhibitor	[3]

References

• [1] Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
• [2] Inhibition of lysoPAF acetyltransferase activity by flavonoids. Inflamm Res. 1996 Nov;45(11):546-9.
• [3] Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43.
• [6] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [7] Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9.
• [8] Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
• [9] Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70.
• [10] Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
• [11] Rubitecan. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9.
• [12] Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol. 2014 Dec;74(6):1125-37.
• [13] Modulation by flavonoids of PAF and related phospholipids in endothelial cells during oxidative stress. J Lipid Res. 2003 Feb;44(2):380-7.
• [14] Binding of cephalothin and cefotaxime to D-ala-D-ala-peptidase reveals a functional basis of a natural mutation in a low-affinity penicillin-binding protein and in extended-spectrum beta-lactamases. Biochemistry. 1995 Jul 25;34(29):9532-40.
• [15] A 1.2-A snapshot of the final step of bacterial cell wall biosynthesis. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1427-31.
• [16] Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol. 2007 Jun;2:297-307.
• [17] How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
• [18] Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors. J Med Chem. 2009 Oct 8;52(19):6097-106.
• [19] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [20] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [21] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.